Bioreactor Articles & Analysis
18 news found
ExcellGene, a renowned Swiss biologics CDMO specializing in complex protein manufacturing services, using standard CHO and HEK293 expression systems and Capricorn Scientific, a leading German manufacturer of high-quality cell culture products, have joined forces in a strategic partnership to elevate the field of biopharmaceutical ...
The collaboration showed that ultrapure antigen preparations made by scientists and engineers at ExcellGene in Monthey with the help of Chinese Hamster Ovary (CHO) cells in bioreactors are highly immunogenic in animals and potentially in humans and can be made in very large quantities. In fact, ExcellGene demonstrated that a single 40 L bioreactor based ...
Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors using Pro10™, the leading cell line on the market Viralgen Vector Core (Viralgen), an independently operated subsidiary of ...
ByBayer AG
The company’s quality-assured, patented bioprocess workflow and unique bioreactors have been proven to increase productivity 20- to 60-fold. “Molecular Devices has the capability, reputation, reach, and resources to ensure that the Cellesce technology can be further developed, and used to its full potential,” said Vicky Marsh-Durban, CEO of Cellesce. ...
Tune into this free webinar to learn about: AAV biology and its use in cell and gene therapies State-of-the-art production of cell and gene therapies Current process intensification methods: cell line and vector engineering, media optimization, and bioreactor design to increase yields New strategies to properly attenuate anti-viral defences in the production system: viral ...
“The ability to streamline vendor management, better control timeline risks, and accelerate end-to-end AAV manufacturing are important differentiators when upscaling to our 5,000L cGMP bioreactors for clients and patients. We are excited to present the data supporting our now-available services at BioProcess International East this ...
Total capital raised of $330 million since the Company’s launch in 2020 Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5,000L bioreactors for research-to-commercial gene therapy manufacturing Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it ...
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced today that they have entered ...
Subsequently, therapeutic enzymes are expressed in a cell culture bioreactor to robust the reproducible protein purification or downstream processing (DSP) of the target product. ...
Cellistic’s services are designed to address significant unmet needs from therapeutic developers in allogeneic cell therapy, including immediate access to a broad range of differentiation and bioreactor-based expansion protocols; comprehensive, scalable cGMP capacity; analytical support; and clinical readiness support for global regulatory submissions. ...
Biostage's existing patents on the bioreactor and scaffold also protect this bronchial indication. This new patent now gives Biostage the protection needed to develop a business in treating lung cancer via the regeneration and repair of the bronchus. ...
Within these protective micro-environments, stem cells can achieve optimal growth in large-scale bioreactors, and can be differentiated into ready-to-transplant 3D microtissues. ...
The scaffold is coated with cells taken from the patient which are incubated in a rotating bioreactor for several days prior to implant. The cellularized scaffold is used to surgically replace the part of the esophagus (e.g., the cancerous part) that has been removed by the surgeon. ...
In many respects, what is going on inside a bioreactor or within downstream operations is still a black box to us.” Mr. ...
At scale, and following product approval, the agreement will absorb a significant proportion of the capacity of the large-scale mammalian asset under construction in Visp, which will accommodate six 20,000L bioreactors. Together with other customers, approximately 75% of the facility’s available capacity is now reserved. ...
The news comes on the heels of the company’s April 2021 announcement regarding the production of a single batch of 15 billion hiPSC in a 10L bioreactor, with an unprecedented amplification factor of 276x in 6.59 days. ...
” Matica Bio’s GMP facility is scheduled to open in Q3 2021 utilizing a bioreactor-based platform, with access to GMP production slots beginning in early 2022. ...
” Matica Bio’s Texas facility is scheduled to open in Q3 2021 utilizing a bioreactor-based platform. Matica Bio’s development and operations staff average over 10 years in the viral vector CDMO industry, bringing a wealth of knowledge and operational experience together to drive our clients’ product development success. ...